Strategies for the management of diabetic dyslipidaemia

Drugs

Volumn 58, Issue SUPPL. 1, 1999, Pages 47-51

  Taskinen, Marja Riitta ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONFERENCE PAPER; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK ASSESSMENT;

ANTILIPEMIC AGENTS; ARTERIOSCLEROSIS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERLIPIDEMIAS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; RISK FACTORS; SIMVASTATIN;

EID: 0032724923     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199958001-00011     Document Type: Article

References (29)

1. Pyörälä K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an epidemiological view. Diabetes Metab Rev 1987; 3: 463-524
2. Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434-44
3. Granger CB, Califf RM, Young S, et al. Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. 1 Am Coll Cardiol 1993:21:920-5
4. Mueller HS, Cohen LS, Braunwald E, et al. Predictors of early mortality and morbidity after thrombolytic therapy of acute myocardial infarction. Analyses of patient subgroups in the Thrombolysis in Myocardial Infarction (TIMI) trial, phase II. Circulation 1992; 85: 1254-64
5. Orlander PR, Goff DC, Morrissey M, et al. The relation of diabetes to the severity of acute myocardial infarction and postmyocardial infarction survival in Mexican-Americans and non-Hispanic whites. Diabetes 1994; 43: 897-902
6. Stein B, Weintraub WS, Gebhart SP, et al. Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. Circulation 1995; 91: 979-89
7. Vigorito C, Betocchi S, Bonzani G, et al. Severity of coronary artery disease in patients with diabetes mellitus: angiographie study of 34 diabetic and 120 nondiabetic patients. Am Heart J 1980: 100 (6 Pt 1): 782-7
8. Miettinen H, Lehto S, Salomaa V, et al. Impact of diabetes on mortality after the first myocardial infarction. The F1NMON1CA Myocardial Infarction Register Study Group. Diabetes Care 1998; 21: 69-75
9. IDF Task Force on Diabetes Health Economics. Costing Diabetes: the cost of prevention. Brussels: International Diabetes Federation, 1997
10. Syvänne M, Taskinen M-R. Lipids and lipoproteins as coronary risk factors in non-insulin-dependent diabetes mellitus. Lancet 1997; 350 Suppl. 1: S120-3
11. Austin MA, Edwards KL. Small, dense low density lipoproteins, the insulin resistance syndrome and noninsulindependent diabetes. Curr Opin Lipidol 1996; 7: 167-71
12. James RW, Pometta D. The distribution profiles of very low density and low density lipoproteins in poorly-controlled male, type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1991; 34: 246-52
13. Howard BJ. Lipoprotein metabolism in diabetes mellitus. J LipidRes 1987; 28: 613-28
14. Taskinen M-R. Hyperlipidaemia in diabetes. Clin Endocrinol Metab 1990; 4: 743-75
15. Gibbons GF. Hyperlipidaemia of diabetes. Clin Sei 1986; 71: 477-86
16. Taskinen M-R. Triglycéride is the major atherogenic lipid in NIDDM. Diabetes Metab Rev 1997; 13: 93-8
17. Fontbonne A, Eschwege E, Cambien F, et al. Hypertriglyceridaemia as a risk factor for coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes: results from the 11-year follow-up of the Paris Prospective Study. Diabetologia 1989; 32: 300-4
18. Laakso M, Lehto S, Penttilä I, et al. Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes. Circulation 1993; 88: 1421-30
19. Hanefeld M, Fischer S, Julius U, et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996; 39: 1577-83
20. Lehto S, Rönnemaa T, Haffner SM, et al. Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes 1997; 48: 1354-9
21. Turner RC, Milln.s H, Neil HA, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus. United Kincdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998; 316: 823-8
22. Taylor R, Agius L. The biochemistry of diabetes. Biochem J 1988; 250: 625-40
23. Brownlee M, Vlassara H, Cerami A. Non-enzymatic glycosylation and the pathogenesis of diabetic complications. Ann Intern Med 1984; 101:527-37
24. De Graaf J, Hak-Lemmers HLM, Hectors MPC, et al. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler Thrombi 991; 11:298-306
25. Mäkimattila S, Liu M-I, Vakkilainen J, et al. Impaired endothelium-dependent vasodilation in type 2 diabetes: relation to LDL size, oxidized LDL and antioxidants. Diabetes Care 1999; 22: 973-81
26. Pyörälä K, Pedersen TR, Kjekshus J, et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997; 20:614-20
27. Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the Cholesterol And Recurrent Events (CARE) Trial. Circulation 1998; 98: 2513-9
28. American Diabetes Association. Management of dyslipidemia in adults with diabetes. Diabetes Care 1999;22SuppI. 1:56-9
29. Dunn CJ, Peters DH. Metformin: a review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs 1995; 49: 721-49